Leonid Timashev
Stock Analyst at RBC Capital
(4.22)
# 755
Out of 5,182 analysts
166
Total ratings
55.41%
Success rate
13.14%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Outperform | $73 → $79 | $67.22 | +17.52% | 4 | Apr 27, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $140 → $162 | $142.95 | +13.33% | 3 | Apr 14, 2026 | |
| INSM Insmed | Maintains: Outperform | $212 → $216 | $137.18 | +57.46% | 9 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $49 → $53 | $29.44 | +80.03% | 6 | Apr 14, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Sector Perform | $11 → $7 | $4.78 | +46.44% | 3 | Mar 18, 2026 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $18 → $14 | $4.22 | +231.75% | 2 | Mar 17, 2026 | |
| LEGN Legend Biotech | Maintains: Outperform | $66 → $62 | $22.85 | +171.33% | 16 | Mar 11, 2026 | |
| DSGN Design Therapeutics | Maintains: Outperform | $13 → $14 | $12.89 | +8.61% | 11 | Mar 10, 2026 | |
| NUVB Nuvation Bio | Maintains: Outperform | $12 → $13 | $4.52 | +187.61% | 5 | Mar 3, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $22 → $23 | $10.02 | +129.54% | 15 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $46 → $43 | $45.36 | -5.20% | 4 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $417 → $425 | $299.01 | +42.14% | 6 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $45 | $34.00 | +32.35% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $191 → $195 | $202.05 | -3.49% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $219 → $222 | $187.51 | +18.39% | 16 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $101 | $62.58 | +61.39% | 7 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $8.83 | +149.29% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $29.99 | +56.72% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $7.69 | +69.05% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.76 | +184.09% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $0.94 | +325.60% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $31.34 | +59.54% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $12.94 | +46.89% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.45 | +138.53% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.82 | +30.89% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.12 | +167.86% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $97.48 | -28.19% | 1 | Jan 23, 2025 |
CG Oncology
Apr 27, 2026
Maintains: Outperform
Price Target: $73 → $79
Current: $67.22
Upside: +17.52%
Revolution Medicines
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $162
Current: $142.95
Upside: +13.33%
Insmed
Apr 14, 2026
Maintains: Outperform
Price Target: $212 → $216
Current: $137.18
Upside: +57.46%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Outperform
Price Target: $49 → $53
Current: $29.44
Upside: +80.03%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Sector Perform
Price Target: $11 → $7
Current: $4.78
Upside: +46.44%
Perspective Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $18 → $14
Current: $4.22
Upside: +231.75%
Legend Biotech
Mar 11, 2026
Maintains: Outperform
Price Target: $66 → $62
Current: $22.85
Upside: +171.33%
Design Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $12.89
Upside: +8.61%
Nuvation Bio
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.52
Upside: +187.61%
Biohaven
Mar 3, 2026
Maintains: Outperform
Price Target: $22 → $23
Current: $10.02
Upside: +129.54%
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $45.36
Upside: -5.20%
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $299.01
Upside: +42.14%
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $34.00
Upside: +32.35%
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $202.05
Upside: -3.49%
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $187.51
Upside: +18.39%
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $62.58
Upside: +61.39%
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $8.83
Upside: +149.29%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $29.99
Upside: +56.72%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $7.69
Upside: +69.05%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.76
Upside: +184.09%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $0.94
Upside: +325.60%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $31.34
Upside: +59.54%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $12.94
Upside: +46.89%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.45
Upside: +138.53%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.82
Upside: +30.89%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.12
Upside: +167.86%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $97.48
Upside: -28.19%